Group IIA secreted phospholipase A 2 in human serum kills commensal but not clinical Enterococcus faecium isolates
Preprint
Abstract
Human innate immunity employs cellular and humoral mechanisms to facilitate rapid killing of invading bacteria. The direct killing of bacteria by human serum is mainly attributed to the activity of the complement system that forms pores in Gram-negative bacteria. Although Gram-positive bacteria are considered resistant to serum killing, we here uncover that normal human serum effectively kills Enterococcus faecium. Comparison of a well-characterized collection of commensal and clinical E. faecium isolates revealed that human serum specifically kills commensal E. faecium strains isolated from normal gut microbiota, but not clinical isolates. Inhibitor studies show that the human group IIA secreted phospholipase A2 (hGIIA), but not complement, is responsible for killing of commensal E. faecium strains in human normal serum. This is remarkable since hGIIA concentrations in ‘non-inflamed’ serum were considered too low to be bactericidal against Gram-positive bacteria. Mechanistic studies showed that serum hGIIA specifically causes permeabilization of commensal E. faecium membranes. Altogether, we find that a normal serum concentration of hGIIA effectively kills commensal E. faecium and that hGIIA resistance of clinical E. faecium could have contributed to the ability of these strains to become opportunistic pathogens in hospitalized patients. Importance: Human normal serum contains antimicrobial components that effective kill invading Gram-negative bacteria. Although Gram-positive bacteria are generally considered resistant to serum killing, here we show that normal human effectively kills the Gram-positive Enterococcus faecium strains that live as commensals in the gut of humans. In contrast, clinical E. faecium strains that are responsible for opportunistic infections in debilitated patients are resistant against human serum. The key factor in serum responsible for killing is group IIA secreted phospholipase A2 (hGIIA) that effectively destabilizes commensal E. faecium membranes. We believe that hGIIA resistance by clinical E. faecium could have contributed to the ability of these strains to cause opportunistic infections in hospitalized patients. Altogether, understanding mechanisms of immune defense and bacterial resistance could aid in further development of novel anti-infective strategies against medically important multidrug resistant Gram-positive pathogens.Keywords
All Related Versions
- Published version: Infection and Immunity, 86 (8).
This publication has 50 references indexed in Scilit:
- Emergence of Epidemic Multidrug-Resistant Enterococcus faecium from Animal and Commensal StrainsmBio, 2013
- Restricted Gene Flow among Hospital Subpopulations of Enterococcus faeciummBio, 2012
- Enterococcus faecium Stimulates Human Neutrophils via the Formyl-Peptide Receptor 2PLOS ONE, 2012
- Conserved domains and evolution of secreted phospholipases A2The FEBS Journal, 2011
- A Novel Bacterial Resistance Mechanism against Human Group IIA-Secreted Phospholipase A2: Role of Streptococcus pyogenes Sortase AThe Journal of Immunology, 2011
- The Antibacterial Lectin RegIIIγ Promotes the Spatial Segregation of Microbiota and Host in the IntestineScience, 2011
- Human Transferrin Confers Serum Resistance against Bacillus anthracisJournal of Biological Chemistry, 2010
- Pyrosequencing-based comparative genome analysis of the nosocomial pathogen Enterococcus faecium and identification of a large transferable pathogenicity islandBMC Genomics, 2010
- Neutrophils Are Essential for Rapid Clearance ofEnterococcus faeciumin MiceInfection and Immunity, 2009
- Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?Nature Reviews Microbiology, 2005